Pro Medicus Ltd
ASX:PME
Pro Medicus Ltd
ASX:PME
Price:
111.41 AUD
-0.21%
Market Closed
Updated:
Apr 30, 2024
P/S
Price to Sales
Price to Sales
79.6
Current
64.3
Median
2.4
Industry
Higher
than median
Higher
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=79.6
Market Cap
/
11.6B
Revenue
146.2m
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| AU |
|
Pro Medicus Ltd
ASX:PME
|
11.6B AUD | 79.6 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
32.5B USD | 13.8 | |
| US |
|
Cerner Corp
NASDAQ:CERN
|
27.9B USD | 4.8 | |
| US |
|
Change Healthcare Inc
NASDAQ:CHNG
|
9B USD | 2.6 | |
| JP |
|
M3 Inc
TSE:2413
|
1.1T JPY | 4.9 | |
| US |
|
Inspire Medical Systems Inc
NYSE:INSP
|
7.2B USD | 11.5 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 9.6 | |
| SE |
|
Sectra AB
STO:SECT B
|
42.9B SEK | 25.8 | |
| US |
|
Evolent Health Inc
NYSE:EVH
|
3.2B USD | 1.6 | |
| US |
|
Goodrx Holdings Inc
NASDAQ:GDRX
|
2.8B USD | 3.8 | |
| US |
|
Vocera Communications Inc
NYSE:VCRA
|
2.8B USD | 11.7 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
71.6
2-Years Forward
P/S
56.8
3-Years Forward
P/S
46
You don't have any saved screeners yet
